Sahaj Samadhi冥想与健康促进计划改善晚年抑郁症严重程度及执行功能:双中心随机对照试验研究方案
本研究为双中心、盲法随机对照试验方案,计划纳入192例晚年抑郁症(LLD)患者,随机分配至Sahaj Samadhi冥想(SSM)组或主动对照健康促进计划(HEP)组,在基线、干预后12周及基线后26周评估抑郁严重程度(HAM-D)与执行功能等指标。背景引用的既往RCT显示SSM相比常规治疗缓解率更高(40.0% vs 16.3%;OR 3.36;95%CI 1.06-10.64;p=0.040)。
要点
- SSM为易于实施的冥想辅助策略,既往RCT中缓解率40.0% vs 常规治疗16.3%(OR 3.36;95%CI 1.06-10.64;p=0.040)。
- 本方案为双中心盲法RCT,计划纳入192例LLD患者,比较SSM与主动对照HEP。
- 主要评估HAM-D抑郁严重程度与执行功能,随访至基线后26周。
核心结论
- 本研究应能更明确地评估SSM是否可作为LLD和TR-LLD患者常规临床照护中的辅助策略。
- 若SSM效果显著优于HEP,将为常规使用该干预管理LLD/TR-LLD及共病执行功能障碍提供支持。
- 研究结果还可为SSM能否改善/预防LLD认知衰退提供信息。
研究设计与样本
- 双中心、盲法、随机对照试验方案,招募192例晚年抑郁症(LLD)患者。
- 两个中心分别位于加拿大安大略省伦敦市(London, ON, Canada)与魁北克省蒙特利尔市(Montreal, QC, Canada)。
- 按中心和是否存在难治性晚年抑郁症(TR-LLD)进行分层随机,分配至SSM组或HEP组。
- 评估时间点为基线(0周)、干预后(12周)及基线后26周。
- 评估者、临床医生和照护提供者对分组设盲,参与者对研究假设设盲。
主要发现
- 背景引用的既往RCT显示,SSM组症状缓解率为40.0%,常规治疗组为16.3%(OR 3.36;95%CI 1.06-10.64;p=0.040)。
- 近期估计当前晚年抑郁症患病率为11%,终生患病率为16-20%。
- LLD导致认知障碍,并使痴呆风险增加近两至三倍。
关键数值与推荐
- 主要评估指标包括使用汉密尔顿抑郁量表(HAM-D)评估的抑郁严重程度变化与执行功能变化。
- 其他探索性指标包括生理学和基于情绪的测量。
- 样本量为192例(n=192)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent estimates suggest an 11% prevalence of current late-life depression (LLD) and a lifetime prevalence of 16-20%. LLD leads to cognitive disturbance as well as a nearly two to three times increased risk of dementia. We conducted a recent randomized controlled trial (RCT) which demonstrated that Sahaj Samadhi meditation (SSM), an easy-to-implement, meditation-based augmentation strategy, led to higher rates of symptom remission when compared to treatment as usual (40.0 vs 16.3%; odds ratio, 3.36; 95% CI 1.06-10.64; p = 0.040). Here we present a protocol describing a two-site, blinded, RCT, comparing an SSM arm to an active-control arm - a Health Enhancement Program (HEP) intervention - in their ability to reduce depressive symptoms and improve executive functioning, among several other exploratory outcomes. METHODS/DESIGN: One hundred and ninety-two (n = 192) participants with LLD will be recruited at two sites (London, ON, Canada, and Montreal, QC, Canada). Participants will undergo stratified randomization with regards to site and the presence of treatment-resistant-LLD (TR-LLD) or not, to either SSM or HEP. We will assess change in (1) depression severity using the Hamilton Depression Rating Scale (HAM-D), (2) executive functioning, and (3) other exploratory physiological and mood-based measures, at baseline (0 weeks), post intervention (12 weeks), and 26 weeks after baseline. Raters, clinicians, and care providers will be blinded to group allocation while participants will be blinded to the study hypotheses. DISCUSSION: This study should more definitively assess whether SSM can be used as an augmentation strategy in routine clinical care for patients suffering from LLD and TR-LLD. If the effects of SSM are significantly better than HEP, it will offer support for the routine use of this intervention to manage LLD/TR-LLD and comorbid declines in executive dysfunction. The results of this study could also inform whether SSM can improve/prevent cognitive decline in LLD. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03564041 . Registered on 20 June 2018.
引用
- Peckham SB, Ionson E, Nassim M, et al. Sahaj Samadhi meditation vs a Health Enhancement Program in improving late-life depression severity and executive function: study protocol for a two-site, randomized controlled trial. Trials. 2019. PMID: 31651355. doi:10.1186/s13063-019-3682-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。